PET, PET imaging, PET-CT, FDG PET, PET cancer assessment, nuclear imaging, molecular imaging

A PET-CT head and neck cancer scan showing various image reconstructions. The top left image is the separate CT scan showing the anatomy. The top right scan shows the fused PET and CT scans with false color added to help interpret the image. The bottom left scan is an initial FDG PET image showing tracer hot spots in the neck and a lymph node in the right jaw due to cancer. The right bottom image is a delayed enhancement scan showing tracer uptake over time, with normal hot spots in the bladder, kidneys, testicles and brain, which normally have higher metabolic activity. The low-grade gray shading of the anatomy is due to the normal cellular metabolism uptake of the FDG throughout the body. 

Feature | PET Imaging | July 26, 2016 | Dave Fornell
Positron emission tomography (PET) is a nuclear imaging technology (also referred to as molecular imaging) that enabl
UltraSPECT, Xpress3.Cardiac, nuclear imaging, RWJPE, New Jersey, Robert Wood Johnson Physician Enterprise
News | SPECT Imaging | July 25, 2016
UltraSPECT Inc. announced recently that Robert Wood Johnson Physician Enterprise (RWJPE), a multi-specialty, community-...
ASNC, SNMMI, PET standard, Pet cardiac imaging, PET nuclear imaging, perfusion imaging

An example of a cardiac PET-CT imaging, should a color coded image of the left ventricle to help assess myocardial perfusion to detect ischemia using a Siemens scanner.

News | Nuclear Imaging | July 19, 2016
An updated joint American Society of Nuclear Cardiology (ASNC) imaging guidelines and Society of Nuclear Medicine and...
PET, mpMRI, prostate cancer detection, targeted biopsies, University of Michigan study, Morand Piert

The figure shows a Gleason 3+4 prostate cancer (arrows) as identified on T2-weighted (A) and diffusion-weighted (B) MRI, F-18-choline PET (C), as well as PET/MRI (D).

News | Prostate Cancer | July 14, 2016
July 14, 2016 — Adding F-18-choline positron e...
Lantheus, Xenon 133 gas, radiopharmaceuticals, IRE, Institute for Radioelements Belgium
News | Radiopharmaceuticals and Tracers | July 12, 2016
Lantheus Holdings Inc., the parent company of Lantheus Medical Imaging Inc. (LMI), announced the first commercial...
Cell>Point, license agreement, China, United Eastern Pharmaceutical, Oncardia imaging agent
News | Radiopharmaceuticals and Tracers | July 07, 2016
July 7, 2016 — Cell>Point announced in mid-June it has entered into an...
personalized medicine
Feature | Imaging | July 06, 2016 | Greg Freiherr
Mammography may be the most recognizable — and singularly effective — type of personalized medicine, benefitting from...
Feature | Molecular Imaging | July 06, 2016 | Melinda Taschetta-Millane
I recently attended the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in San...
Navidea, Lymphoseek injection, breast cancer detction, scintigraphy, SNMMI 2016
News | Radiopharmaceuticals and Tracers | July 06, 2016
Navidea Biopharmaceuticals Inc. announced results from three investigator-initiated studies of the Lymphoseek injection...
University of Southampton, Hodgkin lymphoma, chemotherapy response, bleomycin
News | PET Imaging | June 29, 2016
Hodgkin lymphoma patients can be spared the serious side effects of chemotherapy thanks to high-tech scans that can...
SNMMI, appropriate use criteria, AUC, PAMA, qualified provider-led entity, PLE
News | Clinical Decision Support | June 27, 2016
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has been named a qualified provider-led entity (PLE)...
News | Nuclear Imaging | June 24, 2016
Developers of a new portable molecular imaging system debuted their creation at the 2016 Annual Meeting of the Society...
PET-CT, advanced cancer, lean body mass, LBM, SNMMI 2016 study
News | Oncology Diagnostics | June 23, 2016
Cancer patients often experience significant fluctuations in weight and lean body mass (LBM). Neglecting to account for...
blood test, PRRT, neuroendocrine tumors, NETs, somatostatin receptor imaging, SRI, SNMMI 2016 study

NET circulating transcript and chromogranin A (CgA) levels in responders and non-responders. a) Transcripts were significantly reduced at 6-month follow-up compared to pre-treatment values. Non-responders (NR) exhibited significantly elevated levels at 6 months (FUP_6m). This was also significantly higher than in responders (R). b) A significant alteration was noted only for CgA in non-responders (NR) at 6 months. c) Pre-PRRT: NET transcript scores were elevated in 94 percent and CgA in 57 percent. d) Responders: NET transcripts decreased in 88 percent of responders (no change in 12 percent). CgA was unchanged in 47 percent, decreased in 21 percent and was elevated in 32 percent. e) Non-Responders: NET transcripts increased in 90 percent (no change in 10 percent). CgA was unchanged in 33 percent, decreased in 40 percent and was elevated in 27 percent. For NET transcripts, no falsely decreased or increased values occurred in responders or non-responders, respectively. Credit: LuGenIum Consortium for Independent Research & Wren Laboratories

News | Oncology Diagnostics | June 23, 2016
Malignant neuroendocrine tumors (NETs) are relatively rare, notoriously difficult to treat, and associated with poor...
PET, neuroinflammation, multiple sclerosis, MS, Adam Rosenberg, SNMMI 2016

A. Increased F-18 TZ3504 uptake was observed in the inflamed lumbar spinal cord of EAE-treated animals in the rat model of MS compared to sham control rats. Representative sagittal, coronal and transverse views of the thoracic and lumbar spine are shown. B. The time activity curve of F-18 TZ3504 uptake in the lumbar spinal cord was significantly higher for the first 30 minutes in EAE-treated rats. C. F-18 TZ3504 was able to cross the blood brain barrier and showed homogeneous distribution in the brain of a healthy nonhuman primate. Image Credit:  Mallinckrodt Institute of Radiology at the Washington University School of Medicine, St. Louis, Mo.

News | PET Imaging | June 23, 2016
The triggers of autoimmune inflammation in multiple sclerosis (MS) have eluded scientists for many years, but molecular...
neuroendocrine tumors, NET, radiotherapy dose, PET, SPECT, SNMMI 2016

Comparison of Ga-68-DOTATOC PET/CT with Y-90 DOTATOC PET/CT. Although the positron associated with Y-90 is rarely emitted, there is still sufficient signal to acquire a quantitative PET/CT image of Y-90 DOTATOC after a therapeutic administration. The white arrows indicate kidneys and the yellow arrows tumor. Credit: University of Iowa

News | Nuclear Imaging | June 23, 2016
Aggressive neuroendocrine cancer is something of a dark horse — a rare, elusive and persevering force linked to...
NSCLC, lung cancer, chemotherapy, FDG PET, SNMMI 2016
News | PET Imaging | June 22, 2016
Non-small cell lung cancers (NSCLC) have a collective reputation for not responding very well to chemotherapy....
VASH collimator, DOE, molecular breast imaging, SNMMI 2016

Adding this variable angle slant hole collimator to an existing breast molecular imaging system allows the system to get six times better contrast of cancer lesions in the breast, providing the same or better image quality while also potentially reducing the radiation dose to the patient by half. Technologies developed at DOE’s Jefferson Lab for the variable angle slant hole collimator are included in two filings to the U.S. Patent and Trademark Office. Image courtesy of DOE’s Jefferson Lab.

News | Breast Imaging | June 21, 2016
Preliminary tests have demonstrated that a new device may enable up to six times better contrast of tumors in the...
prostate cancer, biopsy, PET-CT, Ga-68 PSMA, SNMMI 2016 study, Wolfgang Fendler
News | PET-CT | June 20, 2016
Prostate cancer is the leading cancer among men, second only to skin cancer. With surgical removal at the frontline of...
pretargeted radioimmunotherapy, PIRT, colorectal cancer, radionuclide agents, SNMMI 2016, Sarah Cheal

Illustration of three-step DOTA-PRIT based on targeting with an IgG-scFv bispecific antibody (e.g., huA33-C825 for detection and treatment of colorectal cancer) with dual specificity for a tumor-associated antigen (e.g., GPA33) and M-DOTA haptens (e.g., Lu-177 DOTA). Image courtesy of Memorial Sloan Kettering Cancer Center.

News | Radiopharmaceuticals and Tracers | June 20, 2016
An emerging cancer therapy has colorectal tumors surrounded. Presenters at the 2016 Annual Meeting of the Society of...
Overlay Init